新西兰药房将为经事先治疗后符合资格的肾癌病人提供 " Opdivo " 基金。 New Zealand's Pharmac will fund Opdivo® for eligible kidney cancer patients after prior therapy.

新西兰药房将资助Opdivoí (nivolumab)治疗符合资格的病人,这些病人以前曾接受过抗血管诱变性治疗,但患有经转移的细胞肾脏癌。 New Zealand's Pharmac will fund Opdivo® (nivolumab) for eligible patients with metastatic clear cell renal cell carcinoma who have previously received anti-angiogenic therapy. 这一决定是在2024年6月政府增加资金之后作出的。 This decision follows a government funding increase in June 2024. 欧普迪沃是首个批准用于这种类型癌的免疫疗法,这是新西兰第八个最常见的癌症,在2022年报告了671例新病例. Opdivo is the first immunotherapy approved for this type of kidney cancer, which is the eighth most common cancer in New Zealand, with 671 new cases reported in 2022.